Charles River adds ERS License to CRISPR/Cas9 service offering – Drug Target Review
Drug Target Review |
Charles River adds ERS License to CRISPR/Cas9 service offering
Drug Target Review “The addition of a license from ERS provides our clients with a robust CRISPR/Cas9 gene-editing platform,” said Dr. Iva Morse, Corporate Vice President, Chief Scientific Officer, Global Research Models and Services. “Our offering allows clients to work … |
